Les actualités marquantes du congrès Targeted Anticancer Therapies — TAT 2016

Targeted anticancer therapies congress is dedicated to new drugs in early development. The 2016 session was held in Washington, DC, and took a glimpse on the future of immunotherapy and targeted molecular therapies. The activation of antitumor immunity involves numerous challenges, such as better patient selection, deeper understanding of interactions with gut microbiota, and breakthrough expertise for the engineering of chimeric antigen receptor T-cells. Development of targeted molecular therapies is promising as well, with high-throughput sequencing available in clinical practice for better patient stratification, new agents for the treatment of cell cycle, metabolism, and DNA repair alterations, as well as difficult targets and localizations. Such improvements will soon be available in clinical routine and will undoubtedly improve the management of patients in the near future.